Acadia Skyrockets After Phase 3 Success

Phase 3 trial results for Acadia's (Nasdaq: ACAD  ) drug pimavanserin in treating Parkinson's disease psychosis are in, and the results are very positive. This type of psychosis can affect more than half of all Parkinson's sufferers, and the drug showed statistical significant advantages over a placebo group in reducing hallucinations and delusions. While other anti-psychotics that have been used to treat it off-label, they've been met with only limited success and have sometimes been detrimental to other motor skill treatments for patients, something not found in pimavanserin. The resulting market reaction: Shares of Acadia are up an astounding 140%.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.